首页 > 最新文献

Clinical laboratory最新文献

英文 中文
Retrospective Analysis: Exploring Transfusion Thresholds' Impact on Patients with Sepsis and Renal Failure. 回顾性分析:探讨输血阈值对脓毒症合并肾功能衰竭患者的影响。
IF 0.7 4区 医学 Q4 MEDICAL LABORATORY TECHNOLOGY Pub Date : 2025-01-01 DOI: 10.7754/Clin.Lab.2024.240823
Hongyan Zhao, Hui Cheng, Chaofeng Huang, Maowen Huang, Dan Li, Fangchao Mei

Background: Sepsis with renal failure is a common condition in intensive care units (ICUs) and is associated with poor prognosis. A unified consensus on the optimal transfusion hemoglobin concentration threshold is needed to improve outcomes. This study investigated the effects of different transfusion thresholds during hospitalization on the prognosis of patients with sepsis and renal failure.

Methods: A total of 2,972 patients were included in this study. By using the Medical Information Mart for Intensive Care (MIMIC-IV) database, data from patients with sepsis and renal failure were screened and divided into a low-threshold group (Hb ≤ 7 g/dL) and a high-threshold group (Hb > 7 g/dL) based on the average hemoglobin (Hb) level 24 hours before transfusion. Univariate and multivariate Cox regression analyses and inverse probability weighting were used to compare in-hospital and ICU mortality rates between the two groups. Additionally, 30-day, 60-day, and 90-day survival rates, length of hospital stay, and ICU stay duration were evaluated.

Results: Statistically significant differences in baseline characteristics were observed between the two groups. After propensity score matching to eliminate baseline characteristic differences, it was found that among the Cau¬casian population a higher transfusion threshold significantly reduced the risk of in-hospital mortality (HR, 0.774; 95% CI: 0.613 - 0.978, p < 0.05).

Conclusions: For patients with sepsis and renal failure, transfusion thresholds should be determined by considering the patient's race to achieve individualized transfusion strategies.

背景:脓毒症合并肾功能衰竭是重症监护病房(icu)的常见情况,且与预后不良有关。需要对最佳输血血红蛋白浓度阈值达成统一共识,以改善预后。本研究探讨住院期间不同输血阈值对脓毒症合并肾功能衰竭患者预后的影响。方法:共纳入2972例患者。利用重症监护医疗信息市场(MIMIC-IV)数据库,筛选脓毒症和肾功能衰竭患者的数据,并根据输血前24小时的平均血红蛋白(Hb)水平分为低阈组(Hb≤7 g/dL)和高阈组(Hb > 7 g/dL)。采用单因素和多因素Cox回归分析及逆概率加权比较两组住院和ICU死亡率。此外,还评估了30天、60天和90天的生存率、住院时间和ICU住院时间。结果:两组患者基线特征差异有统计学意义。在倾向评分匹配以消除基线特征差异后,发现在高加索人群中,较高的输血阈值显着降低了住院死亡的风险(HR, 0.774;95% CI: 0.613 ~ 0.978, p < 0.05)。结论:对于脓毒症合并肾功能衰竭患者,输血阈值应考虑患者的种族来确定,以实现个性化的输血策略。
{"title":"Retrospective Analysis: Exploring Transfusion Thresholds' Impact on Patients with Sepsis and Renal Failure.","authors":"Hongyan Zhao, Hui Cheng, Chaofeng Huang, Maowen Huang, Dan Li, Fangchao Mei","doi":"10.7754/Clin.Lab.2024.240823","DOIUrl":"https://doi.org/10.7754/Clin.Lab.2024.240823","url":null,"abstract":"<p><strong>Background: </strong>Sepsis with renal failure is a common condition in intensive care units (ICUs) and is associated with poor prognosis. A unified consensus on the optimal transfusion hemoglobin concentration threshold is needed to improve outcomes. This study investigated the effects of different transfusion thresholds during hospitalization on the prognosis of patients with sepsis and renal failure.</p><p><strong>Methods: </strong>A total of 2,972 patients were included in this study. By using the Medical Information Mart for Intensive Care (MIMIC-IV) database, data from patients with sepsis and renal failure were screened and divided into a low-threshold group (Hb ≤ 7 g/dL) and a high-threshold group (Hb > 7 g/dL) based on the average hemoglobin (Hb) level 24 hours before transfusion. Univariate and multivariate Cox regression analyses and inverse probability weighting were used to compare in-hospital and ICU mortality rates between the two groups. Additionally, 30-day, 60-day, and 90-day survival rates, length of hospital stay, and ICU stay duration were evaluated.</p><p><strong>Results: </strong>Statistically significant differences in baseline characteristics were observed between the two groups. After propensity score matching to eliminate baseline characteristic differences, it was found that among the Cau¬casian population a higher transfusion threshold significantly reduced the risk of in-hospital mortality (HR, 0.774; 95% CI: 0.613 - 0.978, p < 0.05).</p><p><strong>Conclusions: </strong>For patients with sepsis and renal failure, transfusion thresholds should be determined by considering the patient's race to achieve individualized transfusion strategies.</p>","PeriodicalId":10384,"journal":{"name":"Clinical laboratory","volume":"71 1","pages":""},"PeriodicalIF":0.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142977825","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
State-of-the-Art Colorectal Cancer and Advanced Precancerous Lesion Screening: a Multitarget Stool DNA Test. 最先进的结直肠癌和晚期癌前病变筛查:多靶点粪便DNA检测。
IF 0.7 4区 医学 Q4 MEDICAL LABORATORY TECHNOLOGY Pub Date : 2025-01-01 DOI: 10.7754/Clin.Lab.2024.240620
Lena Krammes, Hiba-Tun-Noor A Mahmood, Friederike M B Frondorf, Christian F Scholz, Patrick Becker, Srijana Maharjan, Ayfer E Sever, Santhi V Garapati, Anujan Balasubramaniam, Martin J Knabe, Moritz R Eidens, Matthias M Dollinger

Background: Colorectal cancer (CRC) claims 900,000 lives per year. Colonoscopy offers reliable detection, but with low patient adherence rates. To significantly reduce CRC incidence and mortality, a more convenient screening measure for advanced precancerous lesions (APL) and CRC is urgently needed.

Methods: In this study, the clinical performance of a multitarget stool DNA (mt-sDNA) test combining fecal im-munochemical test (FIT) with the analysis of genetic biomarkers by real-time PCR was evaluated in a cohort of 208 subjects.

Results: The mt-sDNA test showed a sensitivity of 84.2% for CRC (all stages) and 39.6% sensitivity for APL detection with a specificity of 91.5%. Within the APL group, high-grade dysplasia, characterized by the highest risk of further cancer progression, were detected with 75% sensitivity.

Conclusions: The mt-sDNA test represents a significant advancement for non-invasive detection of APL and CRC and bears great potential to enhance CRC prevention, incidence, and mortality.

背景:结直肠癌(CRC)每年夺走90万人的生命。结肠镜检查提供了可靠的检测,但患者依从率较低。为了显著降低CRC的发病率和死亡率,迫切需要一种更便捷的晚期癌前病变(APL)和CRC的筛查手段。方法:本研究对208名受试者进行多靶点粪便DNA (mt-sDNA)检测,并结合粪便免疫化学测试(FIT)和实时荧光定量PCR分析遗传生物标志物。结果:mt-sDNA检测对CRC(所有分期)的敏感性为84.2%,对APL检测的敏感性为39.6%,特异性为91.5%。在APL组中,以癌症进一步进展的最高风险为特征的高度发育不良的检测灵敏度为75%。结论:mt-sDNA检测在无创性检测APL和CRC方面取得了重大进展,在提高CRC的预防、发病率和死亡率方面具有很大的潜力。
{"title":"State-of-the-Art Colorectal Cancer and Advanced Precancerous Lesion Screening: a Multitarget Stool DNA Test.","authors":"Lena Krammes, Hiba-Tun-Noor A Mahmood, Friederike M B Frondorf, Christian F Scholz, Patrick Becker, Srijana Maharjan, Ayfer E Sever, Santhi V Garapati, Anujan Balasubramaniam, Martin J Knabe, Moritz R Eidens, Matthias M Dollinger","doi":"10.7754/Clin.Lab.2024.240620","DOIUrl":"https://doi.org/10.7754/Clin.Lab.2024.240620","url":null,"abstract":"<p><strong>Background: </strong>Colorectal cancer (CRC) claims 900,000 lives per year. Colonoscopy offers reliable detection, but with low patient adherence rates. To significantly reduce CRC incidence and mortality, a more convenient screening measure for advanced precancerous lesions (APL) and CRC is urgently needed.</p><p><strong>Methods: </strong>In this study, the clinical performance of a multitarget stool DNA (mt-sDNA) test combining fecal im-munochemical test (FIT) with the analysis of genetic biomarkers by real-time PCR was evaluated in a cohort of 208 subjects.</p><p><strong>Results: </strong>The mt-sDNA test showed a sensitivity of 84.2% for CRC (all stages) and 39.6% sensitivity for APL detection with a specificity of 91.5%. Within the APL group, high-grade dysplasia, characterized by the highest risk of further cancer progression, were detected with 75% sensitivity.</p><p><strong>Conclusions: </strong>The mt-sDNA test represents a significant advancement for non-invasive detection of APL and CRC and bears great potential to enhance CRC prevention, incidence, and mortality.</p>","PeriodicalId":10384,"journal":{"name":"Clinical laboratory","volume":"71 1","pages":""},"PeriodicalIF":0.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142977833","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Value of Heparin Binding Protein in Early Identification of Sepsis-Induced Coagulopathy Disease and Prognosis. 肝素结合蛋白在脓毒症致凝血病早期诊断及预后中的价值。
IF 0.7 4区 医学 Q4 MEDICAL LABORATORY TECHNOLOGY Pub Date : 2025-01-01 DOI: 10.7754/Clin.Lab.2024.240714
Daorong Wu, Tingyu Wen, Fan Li, Zhixiang Wanyan, Zihao Ma, Peng Ji, Shujun Guo, Rui Li, Ming Xue, Kaijun Fen, Qiuming Song
<p><strong>Background: </strong>The aim of this study was to explore the value of heparin-binding protein (HBP) in the early recognition of sepsis coagulopathy (SIC) and the prognosis of sepsis patients.</p><p><strong>Methods: </strong>A retrospective analysis was performed for 139 patients with sepsis admitted to the Intensive Care Unit (ICU) of Hefei Third People's Hospital from April 2022 through April 2024. The clinical baseline data, disease scores [sequential organ failure (SOFA) score, acute physiology and chronic health status (APACHE II) score, and SIC score], inflammatory markers [HBP, procalcitonin (PCT), and interleukin 6 (IL-6)], coagulation-related indexes [platelet count (PLT), prothrombin time (PT), prothrombin time international normalized ratio (PT-INR), activated partial thromboplastin time (APTT), fibrinogen (Fib), and D dimer (D-D)], and the survival time and 28-day prognosis of all patients were observed. The correlation between HBP and disease scores, inflammatory indexes, and coagulation-related indexes was analyzed. The receiver operating characteristic (ROC) curve was used to analyze the predictive value of HBP for SIC and the value of HBP and SIC score for the prognosis of sepsis, the risk stratification was carried out according to the optimal cutoff value of HBP, the differences in the occurrence of major clinical events under different HBP stratifications were compared, and the Kaplan-Meier survival curve was used to analyze the 28-day cumulative survival rate under different HBP stratifications.</p><p><strong>Results: </strong>Among the 139 patients, 98 developed SIC, 41 did not, 73 died at 28 days, and 66 survived. The disease score, inflammation index, and coagulation-related indexes of the non-SIC group were better than those of the SIC group, and the disease scores, inflammation indexes, and coagulation-related indexes of the survival group were better than those of the death group. Correlation analysis showed that HBP was positively correlated with disease score and inflammation index. Coagulation-related index was positively correlated with PT, APTT, PT-INR, Fib, and D-D, and negatively correlated with PLT, among which HBP had the best correlation with disease score (HBP was best correlated with SIC, SOFA, and APACHE II scores; r = 0.818, 0.847, and 0.829, p < 0.001). ROC analysis showed that HBP had a high efficacy in identifying SIC (AUC = 0.934, sensitivity 96.9%, specificity 87.8%, p < 0.001), and the AUC of HBP and SIC score and their combination for 28-day death prediction were 0.802, 0.773, and 0.844 (p < 0.001), respectively. Compared with the HBP ≤ 118.25 ng/mL group (n = 52), the 28-day mortality rate, SIC incidence, APACHE II, and SOFA scores were higher in the HBP > 118.25 ng/mL group (n = 52) (p < 0.001). Kaplan-Meier survival curve analysis showed that the cumulative survival rate of the HBP > 118.25 ng/mL group was significantly lower than that of the HBP ≤ 118.25 ng/mL group (p < 0.001).</p><p>
背景:本研究旨在探讨肝素结合蛋白(HBP)在脓毒症凝血病(SIC)早期识别及脓毒症患者预后中的价值。方法:对合肥市第三人民医院重症监护病房(ICU) 2022年4月至2024年4月收治的139例脓毒症患者进行回顾性分析。临床基线数据、疾病评分[顺序性器官衰竭(SOFA)评分、急性生理和慢性健康状况(APACHE II)评分和SIC评分]、炎症标志物[HBP、降钙素原(PCT)和白细胞介素6 (IL-6)]、凝血相关指标[血小板计数(PLT)、凝血酶原时间(PT)、凝血酶原时间国际标准化比值(PT- inr)、活化部分凝血活素时间(APTT)、纤维蛋白原(Fib)和D-二聚体(D-D)]、观察患者的生存时间及28天预后。分析HBP与疾病评分、炎症指标、凝血相关指标的相关性。接受者操作特征曲线(ROC)被用来分析预测价值方面对碳化硅和HBP的价值和碳化硅为脓毒症的预后评分,根据最优风险分层进行了截断值方面,主要临床事件的发生的差异在不同HBP层次比较、和kaplan meier生存曲线用于分析不同HBP层次下的28天累积生存率。结果:139例患者中,98例发生SIC, 41例未发生SIC, 73例在28天死亡,66例存活。非SIC组的疾病评分、炎症指标、凝血相关指标优于SIC组,生存组的疾病评分、炎症指标、凝血相关指标优于死亡组。相关分析显示,HBP与疾病评分、炎症指数呈正相关。凝血相关指数与PT、APTT、PT- inr、Fib、D-D呈正相关,与PLT呈负相关,其中HBP与疾病评分相关性最好(HBP与SIC、SOFA、APACHE II评分相关性最好;R = 0.818, 0.847, 0.829, p < 0.001)。ROC分析显示,HBP对SIC有较高的识别效率(AUC = 0.934,敏感性96.9%,特异性87.8%,p < 0.001), HBP与SIC评分及其联合预测28天死亡的AUC分别为0.802、0.773、0.844 (p < 0.001)。与HBP≤118.25 ng/mL组(n = 52)相比,HBP≤118.25 ng/mL组(n = 52) 28天死亡率、SIC发生率、APACHE II和SOFA评分均较高(p < 0.001)。Kaplan-Meier生存曲线分析显示,HBP≥118.25 ng/mL组的累积生存率显著低于HBP≤118.25 ng/mL组(p < 0.001)。结论:HBP对SIC的早期识别和脓毒症的预后评价具有较高的预测价值,ICU中早期HBP > 118.25 ng/mL的脓毒症患者发生SIC及死亡的风险较高。
{"title":"The Value of Heparin Binding Protein in Early Identification of Sepsis-Induced Coagulopathy Disease and Prognosis.","authors":"Daorong Wu, Tingyu Wen, Fan Li, Zhixiang Wanyan, Zihao Ma, Peng Ji, Shujun Guo, Rui Li, Ming Xue, Kaijun Fen, Qiuming Song","doi":"10.7754/Clin.Lab.2024.240714","DOIUrl":"https://doi.org/10.7754/Clin.Lab.2024.240714","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;The aim of this study was to explore the value of heparin-binding protein (HBP) in the early recognition of sepsis coagulopathy (SIC) and the prognosis of sepsis patients.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;A retrospective analysis was performed for 139 patients with sepsis admitted to the Intensive Care Unit (ICU) of Hefei Third People's Hospital from April 2022 through April 2024. The clinical baseline data, disease scores [sequential organ failure (SOFA) score, acute physiology and chronic health status (APACHE II) score, and SIC score], inflammatory markers [HBP, procalcitonin (PCT), and interleukin 6 (IL-6)], coagulation-related indexes [platelet count (PLT), prothrombin time (PT), prothrombin time international normalized ratio (PT-INR), activated partial thromboplastin time (APTT), fibrinogen (Fib), and D dimer (D-D)], and the survival time and 28-day prognosis of all patients were observed. The correlation between HBP and disease scores, inflammatory indexes, and coagulation-related indexes was analyzed. The receiver operating characteristic (ROC) curve was used to analyze the predictive value of HBP for SIC and the value of HBP and SIC score for the prognosis of sepsis, the risk stratification was carried out according to the optimal cutoff value of HBP, the differences in the occurrence of major clinical events under different HBP stratifications were compared, and the Kaplan-Meier survival curve was used to analyze the 28-day cumulative survival rate under different HBP stratifications.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;Among the 139 patients, 98 developed SIC, 41 did not, 73 died at 28 days, and 66 survived. The disease score, inflammation index, and coagulation-related indexes of the non-SIC group were better than those of the SIC group, and the disease scores, inflammation indexes, and coagulation-related indexes of the survival group were better than those of the death group. Correlation analysis showed that HBP was positively correlated with disease score and inflammation index. Coagulation-related index was positively correlated with PT, APTT, PT-INR, Fib, and D-D, and negatively correlated with PLT, among which HBP had the best correlation with disease score (HBP was best correlated with SIC, SOFA, and APACHE II scores; r = 0.818, 0.847, and 0.829, p &lt; 0.001). ROC analysis showed that HBP had a high efficacy in identifying SIC (AUC = 0.934, sensitivity 96.9%, specificity 87.8%, p &lt; 0.001), and the AUC of HBP and SIC score and their combination for 28-day death prediction were 0.802, 0.773, and 0.844 (p &lt; 0.001), respectively. Compared with the HBP ≤ 118.25 ng/mL group (n = 52), the 28-day mortality rate, SIC incidence, APACHE II, and SOFA scores were higher in the HBP &gt; 118.25 ng/mL group (n = 52) (p &lt; 0.001). Kaplan-Meier survival curve analysis showed that the cumulative survival rate of the HBP &gt; 118.25 ng/mL group was significantly lower than that of the HBP ≤ 118.25 ng/mL group (p &lt; 0.001).&lt;/p&gt;&lt;p&gt;","PeriodicalId":10384,"journal":{"name":"Clinical laboratory","volume":"71 1","pages":""},"PeriodicalIF":0.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142977842","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Central Nervous System Relapse in a Patient with Acute Myeloid Leukemia Following Chemotherapy. 急性髓性白血病患者化疗后中枢神经系统复发
IF 0.7 4区 医学 Q4 MEDICAL LABORATORY TECHNOLOGY Pub Date : 2025-01-01 DOI: 10.7754/Clin.Lab.2024.240813
Shanmei Lv, Qing Wang

Background: Acute myeloid leukemia (AML) is a hematologic malignancy. It is the most common form of acute leukemia among adults. Recent treatment advances have drastically improved outcomes for these diseases, but the overall survival (OS) is still exceptionally low due to the infiltration of leukemic cells in the central nervous system (CNS).

Methods: Standard microscopic examination of cells in the cerebrospinal fluid (CSF), analysis of the chemical composition of the cerebrospinal fluid, and to integrate flow cytometry (FCM) to analyze the phenotypic characteristics of cells to find leukemia cells.

Results: Pandy's test was positive in CSF, protein content was measured at 102.60 mg/dL, and leukemia cells were observed under microscopes. It was the gold standard for diagnosis. FCM also found 99.6% leukemia cells (CD33bri/CD13-/HLA-DR+/CD11c+/CD64dim/CD56+/CD117-/CD34-/CD38+/CD45dim/CD19-/CD15+/CD14-). The chromosomal karyotype also showed abnormalities.

Conclusions: Early detection of leukemia cells invading the central nervous system by routine examination in cytogenetic abnormalities, monocytic subtypes of AML patients, such as routine smear examination of CSF, has great clinical value for early detection, diagnosis, and intervention of patients with CNSL.

背景:急性髓性白血病(AML)是一种血液系统恶性肿瘤:急性髓性白血病(AML)是一种血液系统恶性肿瘤。它是成人中最常见的急性白血病。最近的治疗进展大大改善了这些疾病的预后,但由于白血病细胞浸润中枢神经系统(CNS),总体生存率(OS)仍然非常低:方法:对脑脊液(CSF)中的细胞进行标准显微镜检查,分析脑脊液的化学成分,并结合流式细胞术(FCM)分析细胞的表型特征,以发现白血病细胞:结果:脑脊液中潘迪氏试验呈阳性,蛋白质含量测定为 102.60 mg/dL,显微镜下可观察到白血病细胞。这是诊断的金标准。FCM 也发现了 99.6% 的白血病细胞(CD33bri/CD13-/HLA-DR+/CD11c+/CD64dim/CD56+/CD117-/CD34-/CD38+/CD45dim/CD19-/CD15+/CD14-)。染色体核型也显示异常:通过对细胞遗传学异常、单核细胞亚型急性髓细胞白血病患者的常规检查,如脑脊液常规涂片检查,早期发现侵入中枢神经系统的白血病细胞,对中枢神经系统白血病患者的早期发现、诊断和干预具有重要的临床价值。
{"title":"Central Nervous System Relapse in a Patient with Acute Myeloid Leukemia Following Chemotherapy.","authors":"Shanmei Lv, Qing Wang","doi":"10.7754/Clin.Lab.2024.240813","DOIUrl":"https://doi.org/10.7754/Clin.Lab.2024.240813","url":null,"abstract":"<p><strong>Background: </strong>Acute myeloid leukemia (AML) is a hematologic malignancy. It is the most common form of acute leukemia among adults. Recent treatment advances have drastically improved outcomes for these diseases, but the overall survival (OS) is still exceptionally low due to the infiltration of leukemic cells in the central nervous system (CNS).</p><p><strong>Methods: </strong>Standard microscopic examination of cells in the cerebrospinal fluid (CSF), analysis of the chemical composition of the cerebrospinal fluid, and to integrate flow cytometry (FCM) to analyze the phenotypic characteristics of cells to find leukemia cells.</p><p><strong>Results: </strong>Pandy's test was positive in CSF, protein content was measured at 102.60 mg/dL, and leukemia cells were observed under microscopes. It was the gold standard for diagnosis. FCM also found 99.6% leukemia cells (CD33bri/CD13-/HLA-DR+/CD11c+/CD64dim/CD56+/CD117-/CD34-/CD38+/CD45dim/CD19-/CD15+/CD14-). The chromosomal karyotype also showed abnormalities.</p><p><strong>Conclusions: </strong>Early detection of leukemia cells invading the central nervous system by routine examination in cytogenetic abnormalities, monocytic subtypes of AML patients, such as routine smear examination of CSF, has great clinical value for early detection, diagnosis, and intervention of patients with CNSL.</p>","PeriodicalId":10384,"journal":{"name":"Clinical laboratory","volume":"71 1","pages":""},"PeriodicalIF":0.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142977854","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Familial Analysis of Familial Hyperlipidemia Attributed to the Y2184C Mutation of the APOB Gene. 归因于 APOB 基因 Y2184C 突变的家族性高脂血症分析。
IF 0.7 4区 医学 Q4 MEDICAL LABORATORY TECHNOLOGY Pub Date : 2025-01-01 DOI: 10.7754/Clin.Lab.2024.240751
Luping Lou, Chunqin Lu

Background: Familial hyperlipidemia (familial hypercholesterolemia, FH) is an autosomal genetic disorder. It includes type heterozygous familial hyperlipidemia (heterozygous familial hypercholesterolemia). HeFH is mainly caused by mutations in the LDLR, APOB, and PCSK9 genes and is characterized by elevated plasma low-density lipoprotein cholesterol levels.

Methods: We present a case of HeFH attributed to an APOB gene mutation. The whole-genome DNA of peripheral blood was extracted from the blood of the proband and their parents, and the exons of peripheral blood were sequenced through high-throughput sequencing. The selected mutation sites were verified by sequencing using the Sanger method.

Results: A heterozygous mutation, c.6551A>G (p.Y2184C), in exon 26 of the APOB gene (Chr2-21233189) was identified in both the proband and the mother. Combined with the clinical features, HeFH caused by this mutation was initially considered.

Conclusions: For patients with a high degree of clinical suspicion of FH, a definitive diagnosis should be established through genetic testing, enabling patients to receive early treatment and effectively prevent the occurrence of cardiovascular events.

背景:家族性高脂血症(家族性高胆固醇血症,FH)是一种常染色体遗传疾病。它包括杂合型家族性高脂血症(杂合型家族性高胆固醇血症)。HeFH 主要由 LDLR、APOB 和 PCSK9 基因突变引起,以血浆低密度脂蛋白胆固醇水平升高为特征:我们报告了一例因 APOB 基因突变导致的 HeFH 病例。方法:我们发现了一例因 APOB 基因突变而导致的 HeFH 病例。我们从病例及其父母的血液中提取了外周血全基因组 DNA,并通过高通量测序对外周血的外显子进行了测序。采用 Sanger 方法对所选突变位点进行测序验证:结果:在患者及其母亲的 APOB 基因(Chr2-21233189)第 26 号外显子中发现了一个杂合突变,即 c.6551A>G (p.Y2184C)。结合临床特征,初步认为该基因突变导致了 HeFH:结论:对于临床上高度怀疑患有先天性心脏病的患者,应通过基因检测明确诊断,使患者及早接受治疗,有效预防心血管事件的发生。
{"title":"A Familial Analysis of Familial Hyperlipidemia Attributed to the Y2184C Mutation of the APOB Gene.","authors":"Luping Lou, Chunqin Lu","doi":"10.7754/Clin.Lab.2024.240751","DOIUrl":"https://doi.org/10.7754/Clin.Lab.2024.240751","url":null,"abstract":"<p><strong>Background: </strong>Familial hyperlipidemia (familial hypercholesterolemia, FH) is an autosomal genetic disorder. It includes type heterozygous familial hyperlipidemia (heterozygous familial hypercholesterolemia). HeFH is mainly caused by mutations in the LDLR, APOB, and PCSK9 genes and is characterized by elevated plasma low-density lipoprotein cholesterol levels.</p><p><strong>Methods: </strong>We present a case of HeFH attributed to an APOB gene mutation. The whole-genome DNA of peripheral blood was extracted from the blood of the proband and their parents, and the exons of peripheral blood were sequenced through high-throughput sequencing. The selected mutation sites were verified by sequencing using the Sanger method.</p><p><strong>Results: </strong>A heterozygous mutation, c.6551A>G (p.Y2184C), in exon 26 of the APOB gene (Chr2-21233189) was identified in both the proband and the mother. Combined with the clinical features, HeFH caused by this mutation was initially considered.</p><p><strong>Conclusions: </strong>For patients with a high degree of clinical suspicion of FH, a definitive diagnosis should be established through genetic testing, enabling patients to receive early treatment and effectively prevent the occurrence of cardiovascular events.</p>","PeriodicalId":10384,"journal":{"name":"Clinical laboratory","volume":"71 1","pages":""},"PeriodicalIF":0.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142977796","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Atypical Intestinal Behçet's Disease Complicated by Latent Tuberculosis Infection. 不典型肠道behaperet病并发潜伏性结核感染。
IF 0.7 4区 医学 Q4 MEDICAL LABORATORY TECHNOLOGY Pub Date : 2025-01-01 DOI: 10.7754/Clin.Lab.2024.240749
Jing-Jing Wang, Sheng-Qiang Jiang, Zhi-Chun Dong, Xiao-Ying Jin, Ya-Ming Wang, Li-Ying Lou

Background: When Behçet's disease is complicated with gastrointestinal ulcers, it is referred to as intestinal Behçet's disease (BD). Clinically uncommon, this condition can involve the entire gastrointestinal tract, often presenting diagnostic challenges in differentiation from Crohn's disease.

Methods: In this case, atypical BD was diagnosed through endoscopic examination, whereas latent tuberculosis infection (LBTI) was confirmed via T-SPOT and PPD tests.

Results: Methylprednisolone was administered during acute flare-ups to promote rapid ulcer healing. Adalimumab, meanwhile, provided swift treatment for intestinal BD and helped maintain long-term remission in affected patients. Additionally, isoniazid and rifampicin were used for the treatment of LBTI.

Conclusions: This case demonstrates the complex and variable clinical course of BD, characterized by highly atypical presentations. As symptoms continue to develop and worsen over time, TNF-α inhibitors play a pivotal role in achieving long-term remission during treatment.

背景:当白塞氏病并发胃肠道溃疡时,被称为肠白塞氏病(BD)。这种疾病在临床上并不常见,可累及整个胃肠道,在与克罗恩病鉴别诊断时常常遇到困难:该病例通过内窥镜检查确诊为非典型 BD,而潜伏结核感染(LBTI)则通过 T-SPOT 和 PPD 试验得到证实:结果:在急性发作期使用甲基强的松龙促进溃疡快速愈合。同时,阿达木单抗可迅速治疗肠道 BD,并帮助患者维持长期缓解。此外,还使用异烟肼和利福平治疗肺结核:本病例显示了 BD 复杂多变的临床过程,其特点是表现极不典型。由于症状随着时间的推移不断发展和恶化,TNF-α抑制剂在治疗过程中实现长期缓解方面发挥着关键作用。
{"title":"Atypical Intestinal Behçet's Disease Complicated by Latent Tuberculosis Infection.","authors":"Jing-Jing Wang, Sheng-Qiang Jiang, Zhi-Chun Dong, Xiao-Ying Jin, Ya-Ming Wang, Li-Ying Lou","doi":"10.7754/Clin.Lab.2024.240749","DOIUrl":"https://doi.org/10.7754/Clin.Lab.2024.240749","url":null,"abstract":"<p><strong>Background: </strong>When Behçet's disease is complicated with gastrointestinal ulcers, it is referred to as intestinal Behçet's disease (BD). Clinically uncommon, this condition can involve the entire gastrointestinal tract, often presenting diagnostic challenges in differentiation from Crohn's disease.</p><p><strong>Methods: </strong>In this case, atypical BD was diagnosed through endoscopic examination, whereas latent tuberculosis infection (LBTI) was confirmed via T-SPOT and PPD tests.</p><p><strong>Results: </strong>Methylprednisolone was administered during acute flare-ups to promote rapid ulcer healing. Adalimumab, meanwhile, provided swift treatment for intestinal BD and helped maintain long-term remission in affected patients. Additionally, isoniazid and rifampicin were used for the treatment of LBTI.</p><p><strong>Conclusions: </strong>This case demonstrates the complex and variable clinical course of BD, characterized by highly atypical presentations. As symptoms continue to develop and worsen over time, TNF-α inhibitors play a pivotal role in achieving long-term remission during treatment.</p>","PeriodicalId":10384,"journal":{"name":"Clinical laboratory","volume":"71 1","pages":""},"PeriodicalIF":0.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142977853","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Epidemiology and Antibiotic Resistance of Neonatal Invasive Group B Streptococcus Disease: a Retrospective Study in Fuzhou, China, 2012 - 2021. 福州市2012 - 2021年新生儿侵袭性B族链球菌病流行病学及耐药性回顾性研究
IF 0.7 4区 医学 Q4 MEDICAL LABORATORY TECHNOLOGY Pub Date : 2025-01-01 DOI: 10.7754/Clin.Lab.2024.240742
Hui Zhong, Huiyu Chen, Huahong Qiu, Zhihui Wu, Chen Liu, Chengwen Que

Background: Group B streptococcus (GBS) causes neonatal invasive disease, mainly sepsis and meningitis. Understanding the clinical characteristics, laboratory tests, and antibiotic resistance patterns of GBS invasive infections provides reliable epidemiological data for preventing and treating GBS infections.

Methods: Clinical characteristics and laboratory test results from 86 patients with neonatal invasive disease (45 cases of early-onset disease [EOD] and 41 cases of late-onset disease [LOD]) recruited from Fujian Maternity and Child Health Hospital between January 2012 and December 2021 were analyzed.

Results: The number of neonates with invasive GBS infections declined for 10 years. Respiratory symptoms, the first clinical presentation in EOD, were predominant (71.1%), including groan, tachypnea, and cyanosis, whereas LOD more often presented with fever (78%). Pneumonia was the most common complication (57.0%). There were 35 patients (77.8%) with pneumonia and 18 patients (40.0%) with respiratory failure in the EOD cases, which were more than those in LOD cases. Neonates in the EOD cases were more prone to myocardial damage, cerebral injury, and metabolic acidosis than those in the LOD cases. The proportion of purulent meningitis (63.4%) and anemia (29.3%) in LOD was higher than those in EOD. White blood cell count of the EOD group was higher than that of the LOD group, whereas the proportion of patients with leukopenia was lower in the EOD group (24.4%) than in the LOD group (46.3%). All the GBS strains were susceptible to penicillin, ampicillin, linezolid, quinupristin, vancomycin, or tigecycline. Erythromycin and clindamycin resistance rates were 82.6% and 84.9%, respectively. A D-test revealed 48.6% iMLSB phenotype (inducible clindamycin resistant), and cMLSB phenotype (47.3%), L-phenotypes (2.7%), and M-phenotypes (1.4%) were also found.

Conclusions: The number of cases of neonatal invasive GBS infections has decreased in recent years. Patients with invasive GBS-EOD infections have insidious onset symptoms and should be diagnosed early based on clinical symptoms and laboratory examination results. GBS strains are resistant to erythromycin and clindamycin, which is not suitable for prophylactic and empirical treatment in the neonatal population in this region.

背景:B群链球菌(GBS)引起新生儿侵袭性疾病,主要是败血症和脑膜炎。了解GBS侵袭性感染的临床特征、实验室检查和抗生素耐药模式,为预防和治疗GBS感染提供可靠的流行病学数据。方法:分析福建省妇幼保健院2012年1月至2021年12月收治的86例新生儿侵袭性疾病(早发性疾病45例,晚发性疾病41例)的临床特点和实验室检查结果。结果:新生儿侵袭性GBS感染10年呈下降趋势。呼吸道症状是EOD的首要临床表现(71.1%),包括呻吟、呼吸急促和发绀,而LOD更常表现为发烧(78%)。肺炎是最常见的并发症(57.0%)。EOD组肺炎35例(77.8%),呼吸衰竭18例(40.0%),均多于LOD组。与LOD组相比,EOD组新生儿更易发生心肌损伤、脑损伤和代谢性酸中毒。LOD中化脓性脑膜炎(63.4%)和贫血(29.3%)的比例高于EOD。EOD组白细胞计数高于LOD组,而白细胞减少的患者比例(24.4%)低于LOD组(46.3%)。所有GBS菌株均对青霉素、氨苄西林、利奈唑胺、奎努普汀、万古霉素和替加环素敏感。红霉素和克林霉素耐药率分别为82.6%和84.9%。d检验显示iMLSB表型(诱导克林霉素耐药)为48.6%,cMLSB表型(47.3%),l -表型(2.7%)和m -表型(1.4%)也被发现。结论:近年来,新生儿侵袭性GBS感染的病例数有所下降。侵袭性GBS-EOD感染患者发病症状隐匿,应根据临床症状和实验室检查结果及早诊断。GBS菌株对红霉素和克林霉素耐药,不适合在本地区新生儿人群中进行预防性和经验性治疗。
{"title":"Epidemiology and Antibiotic Resistance of Neonatal Invasive Group B Streptococcus Disease: a Retrospective Study in Fuzhou, China, 2012 - 2021.","authors":"Hui Zhong, Huiyu Chen, Huahong Qiu, Zhihui Wu, Chen Liu, Chengwen Que","doi":"10.7754/Clin.Lab.2024.240742","DOIUrl":"https://doi.org/10.7754/Clin.Lab.2024.240742","url":null,"abstract":"<p><strong>Background: </strong>Group B streptococcus (GBS) causes neonatal invasive disease, mainly sepsis and meningitis. Understanding the clinical characteristics, laboratory tests, and antibiotic resistance patterns of GBS invasive infections provides reliable epidemiological data for preventing and treating GBS infections.</p><p><strong>Methods: </strong>Clinical characteristics and laboratory test results from 86 patients with neonatal invasive disease (45 cases of early-onset disease [EOD] and 41 cases of late-onset disease [LOD]) recruited from Fujian Maternity and Child Health Hospital between January 2012 and December 2021 were analyzed.</p><p><strong>Results: </strong>The number of neonates with invasive GBS infections declined for 10 years. Respiratory symptoms, the first clinical presentation in EOD, were predominant (71.1%), including groan, tachypnea, and cyanosis, whereas LOD more often presented with fever (78%). Pneumonia was the most common complication (57.0%). There were 35 patients (77.8%) with pneumonia and 18 patients (40.0%) with respiratory failure in the EOD cases, which were more than those in LOD cases. Neonates in the EOD cases were more prone to myocardial damage, cerebral injury, and metabolic acidosis than those in the LOD cases. The proportion of purulent meningitis (63.4%) and anemia (29.3%) in LOD was higher than those in EOD. White blood cell count of the EOD group was higher than that of the LOD group, whereas the proportion of patients with leukopenia was lower in the EOD group (24.4%) than in the LOD group (46.3%). All the GBS strains were susceptible to penicillin, ampicillin, linezolid, quinupristin, vancomycin, or tigecycline. Erythromycin and clindamycin resistance rates were 82.6% and 84.9%, respectively. A D-test revealed 48.6% iMLSB phenotype (inducible clindamycin resistant), and cMLSB phenotype (47.3%), L-phenotypes (2.7%), and M-phenotypes (1.4%) were also found.</p><p><strong>Conclusions: </strong>The number of cases of neonatal invasive GBS infections has decreased in recent years. Patients with invasive GBS-EOD infections have insidious onset symptoms and should be diagnosed early based on clinical symptoms and laboratory examination results. GBS strains are resistant to erythromycin and clindamycin, which is not suitable for prophylactic and empirical treatment in the neonatal population in this region.</p>","PeriodicalId":10384,"journal":{"name":"Clinical laboratory","volume":"71 1","pages":""},"PeriodicalIF":0.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142977892","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Study on the Clinical Application Value of Serum Inflammatory Markers in Benign Prostatic Hyperplasia. 血清炎症标志物在良性前列腺增生症中的临床应用价值研究
IF 0.7 4区 医学 Q4 MEDICAL LABORATORY TECHNOLOGY Pub Date : 2025-01-01 DOI: 10.7754/Clin.Lab.2024.240607
Shuli Yu, Changhuan Zhang, Wei Zhang, Chunyan Qian, Xiangmin Tong, Hong Yuan

Background: The aim of this study was to explore the clinical application value of serum inflammatory markers in the diagnosis and treatment of benign prostatic hyperplasia (BPH) in elderly men.

Methods: From April 2023 through July 2023, 110 BPH patients and 120 healthy individuals who underwent examinations at our hospital were selected as study subjects. The concentrations of C-reactive protein (CRP), procalcitonin (PCT), serum amyloid A (SAA), complement 3 (C3), and complement 4 (C4) were measured in both groups.

Results: The concentrations of CRP and SAA in the BPH patient group were significantly higher than those in the healthy control group (p < 0.05). There was a significant correlation between BPH and the concentrations of CRP and SAA, but no correlation with PCT, C3, or C4. ROC curve analysis indicates that both SAA and CRP have high diagnostic efficacy for BPH. Furthermore, the combined use of SAA and CRP provides the better diagnostic performance. This combined approach has the potential to support physicians in guiding diagnosis and treatment.

Conclusions: Serum inflammatory markers can serve as independent factors for BPH. Among them, CRP and SAA are significantly positively correlated with BPH, which is of great significance for the non-invasive diagnosis of BPH.

研究背景本研究旨在探讨血清炎症标志物在老年男性良性前列腺增生症(BPH)诊断和治疗中的临床应用价值:方法:选取2023年4月至2023年7月在我院接受检查的110名良性前列腺增生症患者和120名健康人作为研究对象。测量两组患者的 C 反应蛋白(CRP)、降钙素原(PCT)、血清淀粉样蛋白 A(SAA)、补体 3(C3)和补体 4(C4)的浓度:结果:良性前列腺增生患者组的 CRP 和 SAA 浓度明显高于健康对照组(P < 0.05)。良性前列腺增生与 CRP 和 SAA 的浓度有明显相关性,但与 PCT、C3 或 C4 没有相关性。ROC 曲线分析表明,SAA 和 CRP 对良性前列腺增生症都有很高的诊断效力。此外,联合使用 SAA 和 CRP 的诊断效果更好。这种联合方法有望为医生指导诊断和治疗提供支持:结论:血清炎症标记物可作为良性前列腺增生症的独立因素。结论:血清炎症指标可作为良性前列腺增生症的独立因素,其中 CRP 和 SAA 与良性前列腺增生症呈显著正相关,这对良性前列腺增生症的无创诊断具有重要意义。
{"title":"Study on the Clinical Application Value of Serum Inflammatory Markers in Benign Prostatic Hyperplasia.","authors":"Shuli Yu, Changhuan Zhang, Wei Zhang, Chunyan Qian, Xiangmin Tong, Hong Yuan","doi":"10.7754/Clin.Lab.2024.240607","DOIUrl":"https://doi.org/10.7754/Clin.Lab.2024.240607","url":null,"abstract":"<p><strong>Background: </strong>The aim of this study was to explore the clinical application value of serum inflammatory markers in the diagnosis and treatment of benign prostatic hyperplasia (BPH) in elderly men.</p><p><strong>Methods: </strong>From April 2023 through July 2023, 110 BPH patients and 120 healthy individuals who underwent examinations at our hospital were selected as study subjects. The concentrations of C-reactive protein (CRP), procalcitonin (PCT), serum amyloid A (SAA), complement 3 (C3), and complement 4 (C4) were measured in both groups.</p><p><strong>Results: </strong>The concentrations of CRP and SAA in the BPH patient group were significantly higher than those in the healthy control group (p < 0.05). There was a significant correlation between BPH and the concentrations of CRP and SAA, but no correlation with PCT, C3, or C4. ROC curve analysis indicates that both SAA and CRP have high diagnostic efficacy for BPH. Furthermore, the combined use of SAA and CRP provides the better diagnostic performance. This combined approach has the potential to support physicians in guiding diagnosis and treatment.</p><p><strong>Conclusions: </strong>Serum inflammatory markers can serve as independent factors for BPH. Among them, CRP and SAA are significantly positively correlated with BPH, which is of great significance for the non-invasive diagnosis of BPH.</p>","PeriodicalId":10384,"journal":{"name":"Clinical laboratory","volume":"71 1","pages":""},"PeriodicalIF":0.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142977836","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Retraction of: Establishment of Tacrolimus-Induced Diabetes in Rat Model and Assessment of Clinical Treatments for Post-Transplant Diabetes Mellitus in Liver Transplant Recipients. 他克莫司致大鼠糖尿病模型的建立及肝移植后糖尿病的临床治疗评价
IF 0.7 4区 医学 Q4 MEDICAL LABORATORY TECHNOLOGY Pub Date : 2025-01-01 DOI: 10.7754/Clin.Lab.2025.120913
Yj Niu, Zy Shen, C Xu, Cf Li, Xj Liu, Yq Teng, H Chen, L Li, Hm Cheng, Xm Yang, S Mao

This retracts the article DOI: 10.7754/Clin.Lab.2012.120913.

本文撤销文章DOI: 10.7754/Clin.Lab.2012.120913。
{"title":"Retraction of: Establishment of Tacrolimus-Induced Diabetes in Rat Model and Assessment of Clinical Treatments for Post-Transplant Diabetes Mellitus in Liver Transplant Recipients.","authors":"Yj Niu, Zy Shen, C Xu, Cf Li, Xj Liu, Yq Teng, H Chen, L Li, Hm Cheng, Xm Yang, S Mao","doi":"10.7754/Clin.Lab.2025.120913","DOIUrl":"https://doi.org/10.7754/Clin.Lab.2025.120913","url":null,"abstract":"<p><p>This retracts the article DOI: 10.7754/Clin.Lab.2012.120913.</p>","PeriodicalId":10384,"journal":{"name":"Clinical laboratory","volume":"71 1","pages":""},"PeriodicalIF":0.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142982133","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Identification of a Bmh in a Chinese Individual. 一名中国人的 Bmh 鉴定。
IF 0.7 4区 医学 Q4 MEDICAL LABORATORY TECHNOLOGY Pub Date : 2025-01-01 DOI: 10.7754/Clin.Lab.2024.240744
Qing Li, Guojin Ou

Background: The Bombay and para-Bombay blood groups are rare blood types that are significant to clinical blood transfusions. Accurate para-Bombay blood group identification is important for the safety of transfusions.

Methods: Serological and molecular biology methods were used to detect one case of ABO blood type. Genotypes of the para-Bombay blood group in the Chinese population were searched and summarized, and the safety of blood transfusion for this group was discussed.

Results: The ABO genotype of the case was B101/O01 and the FUT1 gene haplotype was c.649T and 881_882 delTT, while the phenotypes were Bmh, h2/h649, Le(a-b-), and Se357/Se357,716.

Conclusions: The h649/h2 FUT1 genotype is newly discovered and is responsible for the para-Bombay blood group in the Chinese population. Accurate identification of this blood group using serology and molecular methods is significant to ensure the safety of blood transfusions.

背景:孟买血型和准孟买血型是罕见的血型,对临床输血有重要意义。准确的准孟买血型鉴定对输血安全至关重要。方法:采用血清学和分子生物学方法对1例ABO血型进行检测。对中国人群的准孟买血型基因型进行了检索和总结,并对该血型输血的安全性进行了讨论。结果:该病例ABO基因型为B101/O01, FUT1基因单倍型为c.649T和881_882 delTT,表型为Bmh、h2/h649、Le(a-b-)和Se357/ se357716。结论:h649/h2 FUT1基因型是中国人群中新发现的类孟买血型。利用血清学和分子方法准确鉴定该血型对保证输血安全具有重要意义。
{"title":"Identification of a Bmh in a Chinese Individual.","authors":"Qing Li, Guojin Ou","doi":"10.7754/Clin.Lab.2024.240744","DOIUrl":"https://doi.org/10.7754/Clin.Lab.2024.240744","url":null,"abstract":"<p><strong>Background: </strong>The Bombay and para-Bombay blood groups are rare blood types that are significant to clinical blood transfusions. Accurate para-Bombay blood group identification is important for the safety of transfusions.</p><p><strong>Methods: </strong>Serological and molecular biology methods were used to detect one case of ABO blood type. Genotypes of the para-Bombay blood group in the Chinese population were searched and summarized, and the safety of blood transfusion for this group was discussed.</p><p><strong>Results: </strong>The ABO genotype of the case was B101/O01 and the FUT1 gene haplotype was c.649T and 881_882 delTT, while the phenotypes were Bmh, h2/h649, Le(a-b-), and Se357/Se357,716.</p><p><strong>Conclusions: </strong>The h649/h2 FUT1 genotype is newly discovered and is responsible for the para-Bombay blood group in the Chinese population. Accurate identification of this blood group using serology and molecular methods is significant to ensure the safety of blood transfusions.</p>","PeriodicalId":10384,"journal":{"name":"Clinical laboratory","volume":"71 1","pages":""},"PeriodicalIF":0.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142977898","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Clinical laboratory
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1